A Phase I/IIa Trial to Evaluate the Safety, Tolerability, PK, and Preliminary Efficacy of Single and Multiple Ascending Doses of YN001 in Healthy Subjects and Multiple Ascending Doses of YN001 in Patient With Coronary Atherosclerosis
Latest Information Update: 08 May 2025
At a glance
- Drugs YN 001 (Primary) ; Rosuvastatin
- Indications Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Beijing Inno Medicine
Most Recent Events
- 30 Apr 2025 Status changed from recruiting to completed.
- 06 Feb 2025 Planned End Date changed from 15 Apr 2025 to 30 Apr 2025.
- 06 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 30 Apr 2025.